BridgeBio Oncology Therapeutics (BBOT) Stock Analysis

What BridgeBio Oncology Therapeutics does

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Key metrics

ETFs linked to BBOT

Broad-market and Healthcare sector ETFs an investor holding BridgeBio Oncology Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BBOT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics trades under the ticker BBOT on NASDAQ.

Which exchange is BBOT listed on?

BBOT is listed on NASDAQ.

What sector does BridgeBio Oncology Therapeutics operate in?

BridgeBio Oncology Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BBOT in a portfolio?

PortView shows BBOT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.